KPC PHARMACEUTICALS,INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.53 CNY | +2.41% |
|
+5.33% | +8.01% |
| Apr. 19 | KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 17 | Kunyao Group Receives Clinical Trial Approval for FMF Drug | MT |
ETFs positioned on KPC Pharmaceuticals,Inc
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.53
CNY
Average target price
25.01
CNY
Spread / Average Target
+11.01%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +8.01% | 2.35B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600422 Stock
- Funds and ETFs KPC Pharmaceuticals,Inc
